Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05087342 · ClinicalTrials.gov registry record · Phase 3

Latino Semaglutide Study

A Phase 3 study, sponsored by Loma Linda University.

Completed
Registry status
Phase 3
Development phase
119
Enrollment target

NCT05087342: Completed Phase 3 study, sponsored by Loma Linda University.

NCT05087342 is a Phase 3 study that has completed, run by Loma Linda University. The registered enrollment target is 119 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05087342, a Phase 3 study, has completed, sponsored by Loma Linda University.

COMPLETED
Registry status
Phase 3
Development phase
119 participants
Enrollment target

Study Summary

The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.

Primary Outcome

Assessment will be based on pounds lost between baseline and final study visit.

Interventions

  • DRUG Placebo
  • DRUG Semaglutide 2.4mg

Trial Details

FieldValue
Enrollment Target 119 participants
Start Date 2022-12-13
Est. Completion 2024-05-29
Phase Phase 3
Loma Linda University

237 total trials

What the finished NCT05087342 record still lists

NCT05087342 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05087342 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05087342 about?

NCT05087342 is a clinical study titled "Latino Semaglutide Study". The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.

What is the current status of trial NCT05087342?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2022-12-13. Estimated completion is 2024-05-29.

What interventions are being tested in trial NCT05087342?

The interventions under investigation include: Placebo (DRUG), Semaglutide 2.4mg (DRUG).

Who is sponsoring clinical trial NCT05087342?

This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05087342's enrollment target sits among peer trials

119 1640th of 2000 higher than 360 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04870762 · 119 participants · Phase 2

    Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

  • NCT05559853 · 119 participants

    Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

  • NCT06564389 · 119 participants · Phase 1

    FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

  • NCT06742801 · 119 participants · NA

    Onyx™ Liquid Embolic IDE Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05087342, the US trial registry maintained by the National Library of Medicine. NCT05087342 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.